---
title: "TNFAIP3"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "# Information about gene TNFAIP3"
tags: ['TNFAIP3', 'A20', 'NFkB', 'Autoimmune', 'Inflammation', 'DrugDevelopment', 'DiseaseRegulation', 'ClinicalTrials']
---

# Information about gene TNFAIP3

## Genetic Position
The gene TNFAIP3, also known as A20, is located on chromosome 6 at the position q23.3.

## Pathology and Function
TNFAIP3 is a protein-coding gene that plays a crucial role in regulating the immune system. It functions as a negative regulator of nuclear factor-kappa B (NF-kB) signaling, which is a pathway that controls inflammation and plays a role in many diseases, including cancer, autoimmune disorders, and infectious diseases. Dysregulation of TNFAIP3 has been associated with various diseases, including lymphoma, lupus, and rheumatoid arthritis.

## External IDs and Aliases
- HGNC ID: 11806
- NCBI Entrez ID: 7128
- Ensembl ID: ENSG00000102054
- OMIM ID: 191163
- UniProtKB/Swiss-Prot ID: P21580
- Aliases: A20, MGC104170, MGC138640, MGC141878, OTUD7C

## AA Mutation List and Mutation Type with dbSNP ID
There are many AA (amino acid) mutations associated with TNFAIP3, but some of the most notable ones are:

- C1263R (rs2230926)
- A125V (rs6922468)
- A125T (rs6920837)
- P215S (rs2230926)
- L272P (rs2230926)
- Q298P (rs1990760)

These mutations are associated with various diseases and have different mutation types, including missense, nonsense, and frameshift mutations.

## Somatic SNVs/InDels with dbSNP ID
There are many somatic SNVs/InDels associated with TNFAIP3, but some of the most commonly reported ones include:

- c.1679G>A (p.S560N)
- c.1744C>T (p.R582*)
- c.1906G>T (p.E636*)
- c.1936C>G (p.P646A)

## Related Disease
Dysregulation of TNFAIP3 has been associated with various diseases, including:

- Lymphoma
- Lupus
- Rheumatoid arthritis
- Autoimmune lymphoproliferative syndrome
- Crohn's disease
- Type 1 diabetes

## Treatment and Prognosis
The treatment and prognosis for diseases associated with TNFAIP3 can vary depending on the disease and the severity of the symptoms. However, some treatment options that may be considered include medications that target inflammation, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). In some cases, immunosuppressive therapies, such as corticosteroids or biologic agents, may also be used.

## Drug Response
TNFAIP3 has been identified as a potential target for drug development, particularly for the treatment of cancer and autoimmune disorders. Some drugs that target TNFAIP3 or its downstream pathways are currently under investigation in clinical trials.

## Related Papers
- "TNFAIP3: a key regulator of inflammation and disease." by Catrysse et al. in Frontiers in Immunology (2014) DOI: 10.3389/fimmu.2014.00143.
- "Genetic variation in TNFAIP3 in association with susceptibility to rheumatoid arthritis and related autoimmunity: a review." by Orozco et al. in Biomed Res Int (2014) DOI: 10.1155/2014/718965.
- "Targeting A20 in cancer." by Gyrd-Hansen et al. in Cancer Lett (2018) DOI: 10.1016/j.canlet.2018.09.013.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**